Core Viewpoint - Yidu Tech (02158) saw a significant stock increase of over 6%, currently trading at 5.94 HKD with a transaction volume of 74.37 million HKD, following the approval of a key laboratory focused on intelligent diagnosis and treatment systems for metabolic syndrome [1] Group 1 - The "Multimodal Intelligent Diagnosis and Treatment System Research and Application Key Laboratory" has been successfully approved, led by Peking University First Hospital with Yidu Tech as a core partner [1] - The laboratory will focus on intelligent diagnosis and treatment for heart-kidney metabolic syndrome, marking a significant milestone in Yidu Tech's commitment to specialized intelligent diagnosis [1] - Yidu Tech will integrate its large model technology capabilities into the laboratory's research chain, providing a solid foundation for the implementation of intelligent diagnosis [1] Group 2 - The development of medical artificial intelligence has entered a phase of value verification through practical application [1] - The establishment of the laboratory exemplifies a collaborative innovation model that integrates industry, academia, research, and medicine [1] - Yidu Tech has partnered with several renowned hospitals in China to establish joint laboratories, supporting research from data governance to model development and system construction [1]
医渡科技尾盘涨超6% 公司与北大医院共建北京市重点实验室 以AI重塑专科诊疗决策